Home › Research › Drug development
Interventions for Cognitive Impairment in Type 2 Diabetes Mellitus: An Umbrella Review of Pharmacological and Lifestyle Strategies, Mechanisms, and Clinical Implications
Ninsiima HI, Daniel EE, Kisakye IN, Mandera I, Ainamani HE, Akambasisa M, Ayebazibwe G, Matovu D.. medRxiv, 2026-10-26
Topic: Drug trials: efficacy and safety
Background Type 2 diabetes mellitus (T2DM) is one of the fastest-growing epidemics associated with cognitive impairment and dementia. This reduces quality of life among patients with diabetes. Several trials on the management of cognitive impairment have been done although their effectiveness and mechanisms are still unclear. Aim To synthesize evidence from systematic reviews and meta-analyses of RCTs examining interventions for cognitive impairment in T2DM, stratified by intervention category, comparator, patient characteristics, mechanisms and clinical outcomes. Methods We identified eleven systematic reviews (n = 213,604 participants) reporting effects of cognitive impairment interventions through comprehensive literature search. Using random effect models, a meta-meta-analysis was conducted and heterogeneity assessed using I² statistics. AMSTAR and GRADE were used to assess for quality of reviews. Subgroup analyses were conducted for intervention category, cognitive severity, age, diabetes duration, sex, and follow-up duration. Result Sodium glucose co-transporter inhibitors showed the strongest cognitive improvement effect (pooled OR = 0.44, 95% CI: 0.35–0.55; SUCRA = 94.5%), followed by GLP-1 receptor agonists (RR/OR = 0.60, 95% CI: 0.50–0.72; SUCRA = 92.1%). Among lifestyle interventions, multi-component exercise was the most effective (SMD = 0.69–1.04). The lower baseline cognition (MMSE < 23) benefited more from GLP-1 receptor agonists (Cohen’s d = -3.00, p < 0.001). Advanced age (≥60 years) and prolonged intervention time (≥24 weeks for medications; ≥6 months for exercise) were associated with greater effects. Female gender showed greater benefit from GLP-1 receptor agonists (HR = 0.63 vs 0.81 for male gender). Conclusions SGLT2 inhibitors and GLP-1 receptor agonists have the greatest effect on cognition in T2DM, and the multi-component exercise as the most effective lifestyle component. The review therefore recommends individualized intervention selection based on patient characteristics and baseline cognitive status. This calls for high quality trials with prolonged follow-up to strengthen the evidence base. PROSPERO Registration The trial was registered in PROSPERO under number CRD420261453178
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Ninsiima, H. I., Daniel, E. E., Kisakye, I. N., Mandera, I., Ainamani, H. E., Akambasisa, M., et al. (2026). Interventions for Cognitive Impairment in Type 2 Diabetes Mellitus: An Umbrella Review of Pharmacological and Lifestyle Strategies, Mechanisms, and Clinical Implications. medRxiv. https://doi.org/10.64898/2026.10.23.26366288
Vancouver
Ninsiima HI, Daniel EE, Kisakye IN, Mandera I, Ainamani HE, Akambasisa M, et al. Interventions for Cognitive Impairment in Type 2 Diabetes Mellitus: An Umbrella Review of Pharmacological and Lifestyle Strategies, Mechanisms, and Clinical Implications. medRxiv. 2026. doi:10.64898/2026.10.23.26366288.
BibTeX
@article{ninsiima2026-da71abad,
author = {Ninsiima, H. I. and Daniel, E. E. and Kisakye, I. N. and Mandera, I. and Ainamani, H. E. and Akambasisa, M. and Ayebazibwe, G. and Matovu, D.},
title = {{Interventions for Cognitive Impairment in Type 2 Diabetes Mellitus: An Umbrella Review of Pharmacological and Lifestyle Strategies, Mechanisms, and Clinical Implications}},
journal = {medRxiv},
year = {2026},
doi = {10.64898/2026.10.23.26366288},
url = {https://doi.org/10.64898/2026.10.23.26366288}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 8 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- Background Type 2 diabetes mellitus (T2DM) is one of the fastest-growing epidemics associated with cognitive impairment and dementia.
- Result Sodium glucose co-transporter inhibitors showed the strongest cognitive improvement effect (pooled OR = 0.44, 95% CI: 0.35–0.55; SUCRA = 94.5%), followed by GLP-1 receptor agonists (RR/OR = 0.60, 95% CI: 0.50–0.72; SUCRA = 92.1%).
- Advanced age (≥60 years) and prolonged intervention time (≥24 weeks for medications; ≥6 months for exercise) were associated with greater effects.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designmeta-analysis
- Participants213,604
- Effect sizeOR = 0.44; 94.5%; OR = 0.60
- Evidence strengthHigh
How this study scored 16/100
Preprint — not yet peer-reviewed. It scored 63 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. We have no data on times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 39 of the 62 points we could judge it on, which is 63 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (medRxiv) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 12 / 12 | A meta-analysis pooling many studies |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 4 / 10 | Preprint — not yet peer-reviewed. Hosted on a preprint server. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 4 / 4 | 213,604 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | A review of other studies — randomisation is not credited here |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 39 / 62 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 39 of the 62 points we could judge it on is 63 out of 100. |
| Total | 63 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Drug development
Also tagged “metabolic-syndrome”
304 studies in the library carry the topic tag “metabolic-syndrome”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 304 tagged studies.